Europe Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), and End User

Description

List of Tables

The Europe human vaccine adjuvants market was valued at US$ 472.33 million in 2022 and is expected to reach US$ 1,338.00 million by 2030; it is estimated to register a CAGR of 13.9% from 2022 to 2030.

Rising Trend of Personalized Vaccines Drives Europe Human Vaccine Adjuvants Market

Precision or personalized vaccines are a growing trend in the Europe human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient's disease, assisting the production of vaccines tailored to each patient's unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders.

Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine's specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can effectively increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone. Regulatory bodies and healthcare organizations recognize personalized vaccines' potential for enhancing public health outcomes. For instance, in January 2023, BioNTech and the UK government signed a wide-reaching Memorandum of Understanding (MoU) to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030. This has increased funding for research and development initiatives in this field and measures to expedite regulatory routes for personalized vaccines and adjuvants. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the Europe human vaccine adjuvants market.

Europe Human Vaccine Adjuvants Market Overview

Germany is one of the top pharmaceutical markets in Europe and worldwide. According to Germany Trade & Invest (GTAI), it is the biggest pharmaceutical manufacturing location in the European Union, with approximately 600 pharmaceutical companies. According to GTAI, pharmaceutical production volume in Germany reached ~US$ 61.8 billion (~ 56.5 billion) in 2022. Further, the country ranks second in biopharmaceutical production after the US, which is attributed to favorable industrial infrastructure, a sustainably growing local chemicals industry, and highly qualified workforce availability. According to the same source, the pharmaceutical industry in Germany invested almost US$ 9.5 billion (~ 8.8 billion) in R&D in 2021, which is higher than the amounts invested in the R&D of any other industry. Catering to the largest population in Europe, Germany's healthcare sector is a highly attractive market with significant growth opportunities. A steady increase in life expectancy levels has led to a rise in chronic and age-related illnesses. An increase in the prevalence of infectious diseases is expected to fuel the demand for vaccinations. For instance, according to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, Germany has a population of 36.6 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Additionally, Germany has a high prevalence of hepatitis. Improved health awareness due to the prevalence of infectious diseases has further increased consumer demand for drugs, vaccines, and therapies. Thus, the demand for human vaccine adjuvants is growing rapidly in Germany with the flourishing pharmaceutical R&D landscape in pharmaceutical companies, alongside the increasing prevalence of infectious diseases.

Europe Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Europe Human Vaccine Adjuvants Market Segmentation

The Europe human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the Europe human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the Europe human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the Europe human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the Europe human vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe human vaccine adjuvants market share in 2022.

Creative Biolabs Inc, Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc are some of the leading companies operating in the Europe human vaccine adjuvants market.

Product Code: BMIRE00030406

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 Europe Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Chronic Diseases
- 4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
- 4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
- 4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
- 4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - Europe Market Analysis

5.1 Europe Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Europe Human Vaccine Adjuvants Market Forecast Analysis

6. Europe Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant
- 6.1.1 Overview
- 6.1.2 Particulate Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
- 6.2.1 Overview
- 6.2.2 Emulsion Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
- 6.3.1 Overview
- 6.3.2 Combination Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza
- 7.1.1 Overview
- 7.1.2 Influenza: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
- 7.2.1 Overview
- 7.2.2 Hepatitis: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human Papilloma Virus (HPV)
- 7.3.1 Overview
- 7.3.2 Human Papilloma Virus (HPV): Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Overview
- 8.1.2 Pharmaceutical and Biotechnology Companies: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
- 8.2.1 Overview
- 8.2.2 CMOs and CROs: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Human Vaccine Adjuvants Market - Country Analysis

9.1 Europe
- 9.1.1 Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 9.1.1.1 Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 Germany Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.1.2 Germany Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.1.3 Germany Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.2 UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 UK Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.2.2 UK Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.2.3 UK Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.3 France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 France Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.3.2 France Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.3.3 France Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.4 Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.1 Italy Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.4.2 Italy Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.4.3 Italy Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.5 Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.1 Spain Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.5.2 Spain Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.5.3 Spain Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.6 Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.6.1 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.6.2 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.6.3 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Dynavax Technologies Corp
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 CSL Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Seppic SA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 SPI Pharma Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Croda International Plc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Novavax Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Phibro Animal Health Corp
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Creative Biolabs Inc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms